Description

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[3-[(2-furanylmethylene)amino]-2-oxo-1-imidazolidinyl]carbonyl]aminoacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta[S*(E)]]]- is a high-purity, semi-synthetic β-lactam compound primarily utilized as a key pharmaceutical intermediate. Its complex structure is engineered to serve as a crucial building block in the synthesis of advanced cephalosporin antibiotics, offering significant value in the development of new therapeutic agents. This product is essential for research institutions, fine chemical manufacturers, and pharmaceutical companies engaged in the development and production of next-generation antibacterial drugs.

Application

• Pharmaceutical Intermediate: A critical precursor in the multi-step synthesis of novel cephalosporin-class antibiotics.
• Active Pharmaceutical Ingredient (API) Development: Used in research and development for creating new antibacterial compounds with potentially improved efficacy or spectrum of activity.
• Biochemical Research: Serves as a reference standard or a substrate in studies investigating β-lactamase enzyme interactions and antibiotic resistance mechanisms.
• Fine Chemical Synthesis: Employed in custom synthesis and contract manufacturing for producing specialized, high-value chemical entities.

Basic Information

Product Name	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[3-[(2-furanylmethylene)amino]-2-oxo-1-imidazolidinyl]carbonyl]aminoacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta[S*(E)]]]-
CAS No.	61835-48-1
Molecular Formula	C24H24N5O8SNa
Molecular Weight	573.53 g/mol
Synonyms	(6R,7R)-7-[[(2Z)-2-(2-Furyl)-2-[(5-oxo-4,5-dihydro-1H-imidazol-1-yl)imino]acetyl]amino]-3,3-dimethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt; Sodium (6R,7R)-7-[[(2Z)-2-(2-furyl)-2-[(5-oxo-4,5-dihydro-1H-imidazol-1-yl)imino]acetamido]-3,3-dimethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Cefuroxime sodium impurity; Cefuroxime related compound; Cefuroxime sodium intermediate; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid derivative; Sodium cefuroxime impurity.
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency and high purity suitable for pharmaceutical applications. Quality is verified through comprehensive analytical techniques including HPLC, NMR, and mass spectrometry. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting identity, purity, and impurity profiles. We support compliance with cGMP and ICH Q7 guidelines for active pharmaceutical ingredients.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and must be kept under dry, inert conditions to prevent degradation. The storage area should be well-ventilated and away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.